Comparison between qPCR and RNA-seq reveals challenges of quantifying HLA expression.


Journal

Immunogenetics
ISSN: 1432-1211
Titre abrégé: Immunogenetics
Pays: United States
ID NLM: 0420404

Informations de publication

Date de publication:
06 2023
Historique:
received: 22 11 2022
accepted: 11 01 2023
medline: 25 5 2023
pubmed: 28 1 2023
entrez: 27 1 2023
Statut: ppublish

Résumé

Human leukocyte antigen (HLA) class I and II loci are essential elements of innate and acquired immunity. Their functions include antigen presentation to T cells leading to cellular and humoral immune responses, and modulation of NK cells. Their exceptional influence on disease outcome has now been made clear by genome-wide association studies. The exons encoding the peptide-binding groove have been the main focus for determining HLA effects on disease susceptibility/pathogenesis. However, HLA expression levels have also been implicated in disease outcome, adding another dimension to the extreme diversity of HLA that impacts variability in immune responses across individuals. To estimate HLA expression, immunogenetic studies traditionally rely on quantitative PCR (qPCR). Adoption of alternative high-throughput technologies such as RNA-seq has been hampered by technical issues due to the extreme polymorphism at HLA genes. Recently, however, multiple bioinformatic methods have been developed to accurately estimate HLA expression from RNA-seq data. This opens an exciting opportunity to quantify HLA expression in large datasets but also brings questions on whether RNA-seq results are comparable to those by qPCR. In this study, we analyze three classes of expression data for HLA class I genes for a matched set of individuals: (a) RNA-seq, (b) qPCR, and (c) cell surface HLA-C expression. We observed a moderate correlation between expression estimates from qPCR and RNA-seq for HLA-A, -B, and -C (0.2 ≤ rho ≤ 0.53). We discuss technical and biological factors which need to be accounted for when comparing quantifications for different molecular phenotypes or using different techniques.

Identifiants

pubmed: 36707444
doi: 10.1007/s00251-023-01296-7
pii: 10.1007/s00251-023-01296-7
pmc: PMC9883133
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
HLA-C Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

249-262

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI157850
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI150371
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM075091
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Elife. 2016 Feb 15;5:
pubmed: 26880555
Bioinformatics. 2018 Jul 15;34(14):2401-2408
pubmed: 29514179
PLoS Genet. 2022 Jun 6;18(6):e1010212
pubmed: 35666741
Semin Immunol. 2008 Dec;20(6):343-52
pubmed: 18635379
Science. 2018 Jan 5;359(6371):86-90
pubmed: 29302013
Genome Med. 2012 Dec 22;4(12):102
pubmed: 23259685
Trends Genet. 2020 Apr;36(4):298-311
pubmed: 32044115
Immunogenetics. 2020 May;72(4):205-215
pubmed: 32219494
PLoS One. 2012;7(1):e29819
pubmed: 22253788
Nucleic Acids Res. 2020 Jan 8;48(D1):D948-D955
pubmed: 31667505
Int J Immunogenet. 2019 Oct;46(5):307-320
pubmed: 31183978
Front Immunol. 2021 Aug 17;12:707217
pubmed: 34484204
Am J Hum Genet. 2016 Dec 1;99(6):1353-1358
pubmed: 27817866
Nat Commun. 2017 Jun 26;8:15924
pubmed: 28649982
Genes Immun. 2014 Apr-May;15(3):176-81
pubmed: 24500399
Science. 2015 Mar 6;347(6226):1066-7
pubmed: 25745146
Blood. 2014 Dec 18;124(26):3996-4003
pubmed: 25323824
Proc Natl Acad Sci U S A. 2021 Jun 8;118(23):
pubmed: 34021074
Nature. 2019 Mar;567(7746):109-112
pubmed: 30787439
Annu Rev Genomics Hum Genet. 2013;14:301-23
pubmed: 23875801
Science. 1995 Apr 21;268(5209):405-8
pubmed: 7716543
J Viral Hepat. 2019 Jan;26(1):155-161
pubmed: 30267609
J Virol. 2012 Jun;86(12):6979-85
pubmed: 22496224
Science. 2020 Sep 11;369(6509):1318-1330
pubmed: 32913098
Rheumatology (Oxford). 2002 Dec;41(12):1375-9
pubmed: 12468816
Nat Genet. 2009 Dec;41(12):1290-4
pubmed: 19935663
Nat Biotechnol. 2013 Nov;31(11):1015-22
pubmed: 24037425
PLoS Genet. 2019 Apr 22;15(4):e1008091
pubmed: 31009447
J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1763-e1774
pubmed: 33367784
Front Immunol. 2022 Sep 28;13:1007425
pubmed: 36248878
PLoS Pathog. 2018 Sep 4;14(9):e1007257
pubmed: 30180214
Hum Immunol. 2018 Sep;79(9):678-684
pubmed: 30122171
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1363-8
pubmed: 26787888
Nat Rev Immunol. 2012 Dec;12(12):813-20
pubmed: 23175229
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13794-9
pubmed: 20639463
Immunogenetics. 2002 Oct;54(7):447-62
pubmed: 12389093
Genome Med. 2020 Oct 27;12(1):93
pubmed: 33109261
Genome Biol. 2018 Feb 7;19(1):16
pubmed: 29415772
HLA. 2016 May;87(5):338-49
pubmed: 27060357
Nature. 2013 Sep 26;501(7468):506-11
pubmed: 24037378
HLA. 2018 Nov;92(5):271-278
pubmed: 30232844
Science. 2013 Apr 5;340(6128):87-91
pubmed: 23559252
J Immunol. 2015 Apr 15;194(8):3594-600
pubmed: 25754738
Nat Rev Immunol. 2018 May;18(5):325-339
pubmed: 29292391
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Front Immunol. 2022 Oct 17;13:1011829
pubmed: 36325330
J Virol. 2017 Dec 14;92(1):
pubmed: 29070683
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Hum Mol Genet. 2015 Aug 1;24(15):4268-75
pubmed: 25935001
N Engl J Med. 2015 Aug 13;373(7):599-609
pubmed: 26267621
Bioinformatics. 2020 Jun 1;36(12):3905-3906
pubmed: 32330223
Immunogenetics. 2021 Jun;73(3):253-261
pubmed: 33710355
Front Immunol. 2021 Feb 25;12:629059
pubmed: 33717155
J Immunol. 2017 Dec 1;199(11):3892-3899
pubmed: 29055006
G3 (Bethesda). 2015 Mar 17;5(5):931-41
pubmed: 25787242
Dig Dis Sci. 2021 Aug;66(8):2610-2618
pubmed: 32839905
Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2208525120
pubmed: 36574644
Bioinformatics. 2007 May 15;23(10):1294-6
pubmed: 17384015
Rheumatology (Oxford). 2012 Oct;51(10):1765-74
pubmed: 22723597
Nat Genet. 2006 Oct;38(10):1166-72
pubmed: 16998491
Bioinformatics. 2015 Sep 1;31(17):2778-84
pubmed: 25926345
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Nat Genet. 2020 Mar;52(3):247-253
pubmed: 32066938
J Immunol. 2017 Mar 15;198(6):2320-2329
pubmed: 28148735
Eur J Immunol. 2015 Dec;45(12):3454-63
pubmed: 26399450
Methods Mol Biol. 2018;1802:177-191
pubmed: 29858809
Nature. 2011 Apr 28;472(7344):495-8
pubmed: 21499264
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20705-10
pubmed: 24248364
Front Genet. 2022 Jun 13;13:901377
pubmed: 35879986
Nat Commun. 2017 May 18;8:15452
pubmed: 28516912
Immunogenetics. 2019 Mar;71(3):273-282
pubmed: 30706093
Front Immunol. 2020 May 29;11:941
pubmed: 32547543

Auteurs

Vitor R C Aguiar (VRC)

Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, SP, Brazil. vitor@ib.usp.br.
Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. vitor@ib.usp.br.
Broad Institute of MIT and Harvard, Cambridge, MA, USA. vitor@ib.usp.br.

Erick C Castelli (EC)

Molecular Genetics and Bioinformatics Laboratory, Experimental Research Unit, School of Medicine, São Paulo State University, Botucatu, SP, Brazil.

Richard M Single (RM)

Department of Mathematics and Statistics, University of Vermont, Burlington, VT, USA.

Arman Bashirova (A)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Veron Ramsuran (V)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.

Smita Kulkarni (S)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Host-Pathogen Interactions Program, Texas Biomedical Research Institute, San Antonio, TX, USA.

Danillo G Augusto (DG)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Department of Biological Sciences, The University of North Carolina at Charlotte, Charlotte, NC, USA.
Programa de Pós-Graduação em Genética, Universidade Federal do Paraná, Curitiba, PR, Brazil.

Maureen P Martin (MP)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Maria Gutierrez-Arcelus (M)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Mary Carrington (M)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.

Diogo Meyer (D)

Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, SP, Brazil. diogo@ib.usp.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH